Financial insights of GENB

MyFinsight

For the quarter ending 2026-03-31, GENB made $7,224K in revenue. -$69,195K in net income. Net profit margin of -957.85%.

Income Statement	2026-03-31
Collaboration revenue	7,224
Research and development	57,812
General and administrative	13,524
Total operating expenses	71,336
Loss from operations	-64,112
Change in fair value of convertible preferred stock warrant liability	363
Interest expense	182
Interest income	2,913
Foreign currency exchange loss	58
Total other income (expense), net	2,426
Loss before provision for income taxes	-61,686
Provision for income taxes	28
Net loss	-61,714
Net loss attributable to non-controlling interests	-268
Net loss attributable to generate biomedicines, inc. stockholders	-61,446
Convertible preferred stock accrued dividends	7,749
Net loss attributable to generate biomedicines, inc. common stockholders	-69,195

Basic EPS	-1.07
Diluted EPS	-1.07
Basic Average Shares	64,871,295
Diluted Average Shares	64,871,295

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.